How it works:
Regorafenib is a multikinase inhibitor that blocks tumour proliferation and angiogenesis by inhibiting several protein kinases involved in tumour growth and metastasis. It targets both cancer cells and the blood vessels that supply them.
Recommended for:
Adults with metastatic colorectal cancer unresponsive to standard treatments
Patients with unresectable or metastatic GIST after failure of imatinib and sunitinib
Individuals with unresectable or metastatic hepatocellular carcinoma
Only under supervision of an oncologist
Metastatic colorectal cancer following previous therapy
Unresectable or metastatic gastrointestinal stromal tumours
Unresectable or metastatic hepatocellular carcinoma
Take orally, usually 160mg once daily (4 tablets of 40mg) for the first 21 days of each 28-day cycle, followed by 7 days off. Should be taken after meals at the same time each day. Dosage may be adjusted based on the patient's response and tolerance.
Hypersensitivity to regorafenib or any excipients
Severe hepatic impairment
Pregnancy and breastfeeding
Under 18 years of age
Fatigue, weakness
Diarrhoea, nausea, loss of appetite
Elevated liver enzymes
Hand-foot skin reaction (pain, redness, swelling)
Hypertension
Bleeding and infections
Skin rash and dryness
